Axsome Therapeutics (NASDAQ: AXSM) has appointed David Marek to serve as chief commercial officer. Marek joins the New York biotech from Amgen (NASDAQ: AMGN), where he was vice president and general manager of the company’s neuroscience business unit. His experience also includes executive roles at WebMD and Saatchi & Saatchi Healthcare Advertising. Axsome is developing treatments for central nervous system disorders. The company’s pipeline includes late-stage programs in depression, agitation in Alzheimer’s disease, and migraine.